Biosense Webster Announces FDA Submission for Approval of the Varipulse Platform
All 20 participants in a 12-month follow-up study attained acute success from ablation procedures.
Stay updated with breaking news from Jasmina Brooks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
All 20 participants in a 12-month follow-up study attained acute success from ablation procedures.
Johnson & Johnson MedTech's Biosense Webster announced today that it submitted its Varipulse platform to the FDA for premarket approval.
/PRNewswire/ -- Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, today announced European CE mark...
Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, today announced European CE mark approval of the VARIPULSE™ Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AF) using pulsed field ablation (PFA). The VARIPULSE™ Platform is comprised...
J&J MedTech's Biosense Webster unit announced today that it won CE mark approval for its Varipulse pulsed field ablation platform.